JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 86.2%

Neg 86.2% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.